Ustekinumab achieved the highest clinical and endoscopic response rates in chronic pouchitis, while tofacitinib was linked to more adverse events.

Increased colorectal cancer screening rates are significantly associated with declining mortality, though racial and socioeconomic disparities persist.

Twelve fecal metabolites are significantly altered among patients with irritable bowel syndrome compared with healthy control individuals.

Vitamin D deficiency is significantly more common in pediatric vs adult populations with inflammatory bowel diseases.

Patients with obesity hospitalized with acute pancreatitis who receive GLP-1 RAs have a significantly lower mortality and complication rate at 6 months.

Prior upper endoscopy within 3 years of diagnosis is linked to earlier-stage gastric cancer detection and improved overall ...

The FDA will complete the approval process for certain medications in 1 to 2 months, a change from the usual 10-month review.

Achieving sustained virological response after direct-acting antiviral therapy reduces liver-related events among those with decompensated HCV cirrhosis.

The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...

GLP-RAs significantly improved liver histology, liver fat, and metabolic markers in patients with MASLD, outperforming DDP-4 inhibitors but increasing mild GI side effects.

The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.

New code E11.A applies to patients who use lifestyle interventions to show no signs of type 2 diabetes for at least 3 months.